You are here

Our science / Clinical Trials / Find a Trial / NCT01254383

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

Back to Search Print Save as PDF Bookmark Trial

NCT01254383

Last updated on October 4, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Singapore, , 188770 Singapore
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
45+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Otherwise healthy male subjects age 45 years or older with or without erectile
dysfunction.

Body Mass Index (BMI) of 17.5 to 32.5 kg/m2.

Signed and dated informed consent document.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant abnormalities

- Have baseline orthostatic hypotension

- Positive drug screen, excessive alcohol and tobacco use

NCT01254383
Pfizer
Completed
Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Erectile Dysfunction
Caverject User Study
NCT01008605
Males
40+
Years
Multiple Sites
Erectile Dysfunction
Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.
NCT01254396
Males
45+
Years
Singapore,
Erectile Dysfunction
Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction
NCT00862888
Males
18+
Years
Multiple Sites
Erectile Dysfunction
A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
NCT00644956
Males
18+
Years
Multiple Sites
Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.
An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of Sildenafil Following Fasted Administration Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered With Or Without Water Relative To Viagra® Oral Tablet With Water
This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties as the conventional tablet of sildenafil.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Erectile Dysfunction
  • Drug: Sildenafil Tablet
    Tablet, 50 mg, Single Dose
  • Drug: Sildenafil ODT
    Orally Disintegrating Tablet, 50 mg, Single Dose
  • Active Comparator: Treatment A
    Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
    Intervention: Drug: Sildenafil Tablet
  • Experimental: Treatment B
    Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
    Intervention: Drug: Sildenafil ODT
  • Experimental: Treatment C
    Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
    Intervention: Drug: Sildenafil ODT
Damle B, Duczynski G, Jeffers BW, Crownover P, Coupe A, LaBadie RR. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014 Feb 1;36(2):236-44. doi: 10.1016/j.clinthera.2013.12.010. Epub 2014 Jan 18.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
March 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.

Body Mass Index (BMI) of 17.5 to 32.5 kg/m2.

Signed and dated informed consent document.

Exclusion Criteria:

  • Evidence or history of clinically significant abnormalities
  • Have baseline orthostatic hypotension
  • Positive drug screen, excessive alcohol and tobacco use
Sexes Eligible for Study: Male
45 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Singapore
 
 
NCT01254383
A1481289
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now